[go: up one dir, main page]

AR100734A1 - Método para tratar leucemia linfocítica crónica (cll) - Google Patents

Método para tratar leucemia linfocítica crónica (cll)

Info

Publication number
AR100734A1
AR100734A1 ARP150101774A ARP150101774A AR100734A1 AR 100734 A1 AR100734 A1 AR 100734A1 AR P150101774 A ARP150101774 A AR P150101774A AR P150101774 A ARP150101774 A AR P150101774A AR 100734 A1 AR100734 A1 AR 100734A1
Authority
AR
Argentina
Prior art keywords
cll
ibrutinib
individual
chronic lymphocytic
lymphocytic leukemia
Prior art date
Application number
ARP150101774A
Other languages
English (en)
Inventor
Sampath Deepa
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of AR100734A1 publication Critical patent/AR100734A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se revelan métodos y compuestos para el tratamiento de un individuo diagnosticado con leucemia linfocítica crónica (CLL) ó leucemia mieloide aguda (AML) por medio de la administración a dicho individuo de una combinación que comprende ibrutinib y Abexinostat. También se proveen métodos para tratar un ibrutinib- resistente CLL ó un ibrutinib- resistente AML por administración al individuo de una combinación que comprende ibrutinib y Abexinostat. Adicionalmente se proveen métodos de reducción del desarrollo de resistencia a ibrutinib en un individuo que tiene cualquiera de CLL ó AML ó de prevención del desarrollo de resistencia a ibrutinib en un individuo que tiene CLL ó AML por administración al individuo de una combinación que comprende ibrutinib y Abexinostat.
ARP150101774A 2014-06-04 2015-06-04 Método para tratar leucemia linfocítica crónica (cll) AR100734A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462007696P 2014-06-04 2014-06-04

Publications (1)

Publication Number Publication Date
AR100734A1 true AR100734A1 (es) 2016-10-26

Family

ID=54767323

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101774A AR100734A1 (es) 2014-06-04 2015-06-04 Método para tratar leucemia linfocítica crónica (cll)

Country Status (4)

Country Link
US (1) US20150352116A1 (es)
AR (1) AR100734A1 (es)
TW (1) TW201600088A (es)
WO (1) WO2015187848A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210371937A1 (en) * 2016-02-06 2021-12-02 University Health Network Method for identifying high-risk aml patients
SG11201811661TA (en) * 2016-07-29 2019-01-30 Oncternal Therapeutics Inc Uses of indolinone compounds
US20210121466A1 (en) 2018-05-03 2021-04-29 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
EA202190045A1 (ru) * 2018-06-15 2021-03-17 Янссен Фармацевтика Нв Составы/композиции, содержащие ибрутиниб
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115554301A (zh) * 2022-10-24 2023-01-03 徐诺药业(南京)有限公司 Hdac抑制剂和伊布替尼在制备预防或者治疗套细胞淋巴瘤的药物中的用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
US9421208B2 (en) * 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors

Also Published As

Publication number Publication date
WO2015187848A1 (en) 2015-12-10
TW201600088A (zh) 2016-01-01
US20150352116A1 (en) 2015-12-10

Similar Documents

Publication Publication Date Title
PE20180260A1 (es) Metodos y kits para tratar la depresion
AR100734A1 (es) Método para tratar leucemia linfocítica crónica (cll)
CL2016000354A1 (es) Modulación de la inmunidad tumoral
UY34593A (es) Miméticos sintéticos de apelina para el tratamiento de falla cardiaca
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
DOP2017000111A (es) Inhibidor de cinasa aurora a
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
UY34218A (es) MÉTODO DE DETECCIÓN DEL EVENTO DE SOJA pDAB9582.814.19.1
EA201790398A1 (ru) Способы лечения заболевания печени
NZ730809A (en) Methods for treating filoviridae virus infections
MX354217B (es) Composiciones y metodos para el tratamiento de leucemia.
TW201613887A (en) Antiproliferative compounds and methods of use thereof
WO2015110923A3 (en) Btk inhibitor for the treatment of chronic lymphocytic and small lymphocytic leukemia
CL2016000055A1 (es) Métodos para tratar o prevenir afecciones oftalmológicas
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
MX384501B (es) Tratamiento de artritis psoriasica usando apremilast.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
EA202090061A1 (ru) Применение антитела против cd70, argx-110, для лечения острого миелоидного лейкоза
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
CO2017003699A2 (es) Compuesto heterocíclico
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
MX2015014590A (es) Tratamiento de cancer con dihidropirazino-pirazinas.
MX2018004351A (es) Uso de medicamentos con propiedades neuroprotectoras para prevenir o reducir el riesgo del daño por isquemia-reperfusion en un sujeto.
BR112017012911A2 (pt) método para tratamento de insuficiência cardíaca
MX2016014384A (es) Apremilast para el tratamiento de una enfermedad del higado o una anormalidad en la funcion del higado.

Legal Events

Date Code Title Description
FB Suspension of granting procedure